Ambit left to mull options as quizartinib partner Astellas pulls out of alliance
This article was originally published in Scrip
Executive Summary
Ambit Biosciences has been left holding its most advanced drug candidate alone - at least for now - after Astellas exercised its right to end a 2009 global license agreement with the private US firm for the joint development and commercialization of FMS-like tyrosine kinase-3 (FLT3) inhibitors, led by quizartinib.
You may also be interested in...
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.